PORTRAZZA
(Necitumumab)Phase 2Monoclonal antibody
Eli LillyPORTRAZZA is a monoclonal antibody that works as a Epidermal Growth Factor Receptor Erbb1 Inhibitor.[2] It is being investigated across 4 indications, with its most advanced program in Phase 2.[1]
PORTRAZZA is one of 101 small molecule programs targeting Lung Cancer. It is currently in Phase 2.
4
Indications
18
Total Trials
3
Active Trials
100
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
268 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Stivarga
BayerPhase 3
Vectibix
AmgenPhase 3
Bayer Aspirin
BayerPhase 3
Acetylsalicylic Acid
BayerPhase 3
PORTRAZZA
Eli LillyPhase 2
Serplulimab
Shanghai Henlius BiotechPhase 3
Adjuvant Chemotherapy
NNizhny Novgorod Regional Clinical Oncology Center
Phase 3
Cytokine-Induced Killer Cells
TThe First People's Hospital of Changzhou
Phase 3
SHR-A1811
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Clostridium Butyricum
XXijing Hospital of Digestive Diseases
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer7 trials
Show 4 more trials
Lung Cancer4 trials
Metastatic Lung Non-Small Cell Carcinoma2 trials
Advanced Solid Tumors1 trial
3 more indications
Squamous Cell Carcinoma1 trial
Pembrolizumab1 trial
Regulatory
FDA Approval Timeline[4]
Nov 24, 2015
PORTRAZZA
BLA BLA125547
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Necitumumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]